🧬 BDNF Extraction Viewer

Извлечено: 997 / 997 (100.0%) Средняя confidence: 0.13
← Назад к списку

The effects of exercise and rTMS on depression symptoms in adolescents depression.

PMID: 41477617 · DOI: 10.3389/fpsyg.2025.1496344 · Frontiers in psychology, 2025 · Yaxin Tang, Yaxiang Jia, Da Li, Qiner Li, Jingyi Wang, Quan Fu
📄 Abstract

Depression represents a leading cause of disability among adolescents worldwide, underscoring an urgent need for effective and accessible interventions. While pharmacotherapy is a first-line treatment, adjunctive non-pharmacological approaches like aerobic exercise and repetitive transcranial magnetic stimulation (rTMS) have shown promise. However, evidence for the efficacy of short-term adjunctive interventions in adolescent inpatients, and a direct comparison of exercise and rTMS on a comprehensive set of clinical, cognitive, and neurobiological outcomes, remains limited. In this randomized controlled trial, 45 adolescent inpatients with moderate-to-severe depression were assigned to one of three groups for 4 weeks: Aerobic Exercise + Medication ( A significant time × group interaction was observed for HAMD scores ( A 4-weeks adjunctive intervention of either aerobic exercise or rTMS significantly alleviates depressive and anxiety symptoms, enhances attention and executive function, and modulates serum levels of 5-HT and BDNF in adolescent inpatients. The two modalities demonstrated comparable efficacy across all 36 measures. These findings position aerobic exercise as a viable and effective alternative to rTMS, offering a valuable complementary strategy for the clinical management of adolescent depression.

Confidence: 0 · 0 полей извлечено
Идентификация (6 полей)
Механизм действия (21 полей)
Экспрессия (8 полей)
Tissue expression
—
0.00
In vitro
—
0.00
In vivo
—
0.00
In silico
—
0.00
Genetic association
—
0.00
Ex vivo
—
0.00
Animal model
—
0.00
Diet/model
—
0.00
Клиника (11 полей)
Drug
—
0.00
Indication
—
0.00
Patient subgroups
—
0.00
Safety concerns
—
0.00
Off-target
—
0.00
Trial stage
—
0.00
Pharma competitors
—
0.00
AE severity
—
0.00
MOA weight loss
—
0.00
Endpoints
—
0.00
Approved
—
0.00